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Abstract
Background: High concentrations of pro-inflammatory cytokines have been previously observed in the genital fluids of
women enrolled in microbicide trials and may explain observed increased HIV transmission in some of these trials. Although
the longitudinal nature of these studies allows within-subject comparisons of post-product levels to baseline levels, the fact
that the physiologic variations of these cytokines and other markers of immune activation are not fully defined in different
populations, makes it difficult to assess changes that can be directly attributed to microbicide use as opposed to other
biological and behavioural factors.
Methods: Cervicovaginal lavage samples were collected from 30 healthy Caucasian and assayed for concentrations of ten
cytokines/chemokines, total protein content and two antimicrobial proteins using a multiplex immunoassay and ELISA.
Cellular markers were characterized by flow cytometry on mononuclear cells collected from the endocervix using flocked
swabs. Bacterial quantification was performed using quantitative PCR.
Results: Ectopy, menstrual cycle phase, prostate-specific antigen and presence of leucocytes in endocervical cells’
supernatant were associated with the concentrations of cyto-/chemokines in cervicovaginal secretions. Approximately 3%
of endocervical cells collected were monocytes of which a median of 52% (SD =17) expressed both CD4 and CCR5 markers.
Approximately 1% of the total cells were T-cells with a median of 61% (SD =10) CD4 and CCR5 expression. Around 5% of
the monocytes and 16% of the T-cells expressed the immune activation marker HLA-DR. Higher percentages of T-cells were
associated with greater quantities of IL-1RA, GM-CSF and elafin.
Conclusion: We demonstrate the presence of selected soluble and cellular immune activation markers and identify their
predictors in the female genital tract of healthy women. Future clinical trials should consider ectopy, sexual activity,
menstrual cycle phase and presence of bacterial species as possible confounders when evaluating the possible
inflammatory effects of microbicide compounds.
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Introduction
In the HIV prevention campaign, safe and effective anti-HIV
microbicides would offer a discrete protection option when applied
vaginally by women before and/or after sexual intercourse but
also rectally by men who have sex with men (MSM). Though
modest, recent success with the CAPRISA 004 tenofovir gel trial
that conferred 39% protection against HIV infection in sexually
active women in South Africa [1] provided proof of concept and a
much needed impetus in the field of anti-HIV microbicide
development although a subsequent study in a different population
(VOICE) failed to show effectiveness of the vaginal tenofovir gel
[2]. Oral antiretrovirals (ARVs) have also been shown to be
effective pre-exposure chemoprophylactic agents in MSM [3] as
well as in heterosexual discordant couples [4]. Previously, clinical
trials with first generation vaginal microbicide compounds
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effectiveness or resulted in an increased risk of HIV infection in the
subjects who used them although they had proven antiviral activity
in vitro [5,6,7]. It was postulated that the increased infection risk
could have been partially due to microbicide-induced mucosal
inflammation that results in attraction and activation of CD4+
immune cells, which are prime targets for HIV infection. Excessive
inflammation and compound toxicity could also compromise the
cervical and vaginal epithelial integrity exposing sub-epithelial
target cells like dendritic cells (DC’s), CD4+ T-lymphocytes and
macrophages to HIV [8,9]. Either way, a better understanding of
the mucosal immunity and its modulating factors in different
human populations is essential for designing better anti-HIV
microbicides and for characterizing drug effects on HIV trans-
mission.
Efforts are therefore underway to define soluble and cellular
biomarkers that could be used in microbicide trials to assess sub-
clinical mucosal inflammation and hence increase product safety
[10,11,12]. Quantification of soluble biomarkers including pro-
and anti-inflammatory cytokines found in female genital tract
(FGT) secretions has been done in cervicovaginal lavage (CVL)
samples or endocervical secretions (ECS) samples collected using
different types of swabs or sponges. Considerable data has been
generated on cytokine concentrations in the FGT secretions of
HIV-positive [13,14], high risk HIV-negative [13], low risk HIV-
negative [13], microbicide trial participants [15] and even healthy
women [12]. However, methodological variations in sample
collection, processing and assay still present a challenge for
comparison of data between different studies [16], a challenge also
encountered in cytokine measurement in serum and plasma
samples [17,18]. Although attempts have been made to standard-
ize cytokine measurement in the vaginal and blood serum context
[19] and baseline confidence intervals have been published for
some of them in CVLs [19], normative values for these cytokines
and other markers of immune activation have not been defined in
all populations making it hard to assess cytokine variations that
can be attributed to microbicide use as opposed to age, hormonal
changes during the menstrual cycle, vaginal tract infection and
exposure to semen among other factors.
Definition of cellular markers of immune activation in the FGT
of healthy women is also of paramount importance not only
because some of these cells are targets for initial HIV infection, but
in addition, their recruitment to mucosal surfaces propagates local
HIV replication and subsequent systemic dissemination due to
normal immune trafficking mechanisms [20,21]. The healthy
female genital tract is also home to certain bacterial species that
create an acidic environment hostile to pathogens. Imbalance in
the vaginal microbiome can result in bacterial vaginosis (BV) that
has been associated with greater susceptibility to HIV infection
[22]. To our knowledge, there is no study to date that correlates
the above mentioned soluble markers of immune activation with
cellular immune activation markers, the vaginal microbiome and
clinical data all of which are part of the complex FGT
environment targeted in microbicide trials. Generation of data
on the ranges of cytokines/chemokines, local cell populations and
the factors that affect their expression in healthy women is needed
for assessing the safety of future microbicide candidates.
In this study, we report concentrations of selected cytokines,
chemokines and growth factors as well as b-defensin and the anti-
protease elafin in CVLs from healthy women representative of a
typical early phase I trial population and establish clinical factors
associated with their immunoassay detection. We also characterize
by flow cytometry the proportion of T-cells and monocytes, as well
as their expression of the activation marker HLA-DR and the HIV
co-receptor CCR5 in the endocervical canal of these women. The
association between the vaginal microbiome composition with
these soluble and cellular factors is also examined.
Methods
Ethical statement
IRB approval was obtained from the Institute of Tropical
Medicine and from the Ethics Committee at the University
Hospital of Antwerp. All clinical investigations were conducted
according to the principles expressed in the Declaration of
Helsinki. All study participants gave their written informed
consent.
Study subjects
Thirty women aged between 19 and 38 years were recruited at
the Institute of Tropical Medicine in Antwerp, Belgium using a
previously described recruitment strategy for a classical healthy
population for a phase I microbicide trial [23]. These women were
not pregnant, did not use any hormonal contraception for the
duration of the study, they did not have vaginal infections at
screening and had a regular menstrual cycle. Sexual activity was
allowed and condoms were provided. Women were screened and
then scheduled for five follow-up visits on days 7 (+/2 2 in the
follicular phase) and 21 (+/2 2 in the luteal phase) of the three
subsequent menstrual cycles. At each visit, a written questionnaire
was completed by the women about their sexual activity over the
three days preceding the day of sampling.
Sample collection
A clinician collected three high vaginal specimens at each visit,
using flocked synthetic swabs (COPAN Innovation, Italy). Two
swab specimens were used for quantitative PCR for vaginal
bacterial species testing [24] and the third for prostate-specific
antigen (PSA) testing. The swabs were stored at 2–8uC until
transport to the laboratory, where they were stored dry at 220uC
until testing.
For cervicovaginal lavage samples, 10 ml normal saline at room
temperature was flushed using a sterile pipette over the cervix and
the lateral vaginal walls. This fluid was aspirated from the
posterior fornix using the same pipette and collected in a 15 ml
falcon tube that was then put in a cool box with ice (2–8uC). To
collect endocervical cells, a flocked swab was inserted into the
endocervical canal and gently turned over 360u. The swab was
then removed and placed in a falcon tube with 10 ml phosphate
buffered saline (PBS) with 1% foetal calf serum (FCS), L-glutamine
(200 mM) and penicillin/streptomycin (10.000 U/ml). This pro-
cedure was repeated with a second flocked swab that was placed in
the same tube as the first one. The samples were stored in a cool
box together with the CVL samples and immediately transported
to the laboratory for processing.
Sample processing
Sample processing was started within one hour of sample
collection for CVL and within 30 minutes for endocervical cell
samples. CVL samples were centrifuged at 10006 g for
10 minutes at 4uC to get rid of debris and the supernatant
(,9 ml) was aliquoted into five fractions of approximately 1.8 ml
each and stored at 280uC. Processing of the endocervical swab for
cellular markers involved addition of 50 ml of 1M DL-Dithiothre-
itol (Sigma-Aldrich, Belgium) to the 10 ml medium and incubation
for 15 minutes at 37uC to dissolve the mucus. The tube was then
gently vortexed to release the cells from the swab tips, after which
the swab tips were removed and cells centrifuged at 10006g for
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dipsticks, the supernatant was discarded and the cell pellet
resuspended in 1 ml cell culture medium. Twenty five microliters
was then removed for cell counting before analysis was done by
flow cytometry.
Clinical and laboratory diagnostic tests
Estimates of the pH of vaginal secretions were determined by
the study doctor using colour-fixed indicator sticks pH-Fix 3.6–6.1
(Macherey-Nagel GmbH & Co KG, Duren, Germany). These pH
strips are colour-coded with graduations at pH points 3.6, 4.1, 4.4,
4.7, 5.0, 5.3, 5.6 and 6.1 and sample pH values are determined by
comparing the test fields to the colour block (accuracy 60.1 pH).
Vaginal smears were examined using the Nugent scoring system in
which a Nugent score of 7–10 is consistent with BV, 4–6 is an
intermediate score and 0–3 reflects a normal vaginal microbiome
[25]. Participants were also tested for the following sexually
transmitted infections (STIs): Trichomoniasis and Candidiasis
using wet mount analysis; Chlamydia trachomatis – CT and Neisseria
gonorrhoeae – NG using commercial nucleic acid amplification
assays.
PSA testing was performed on vaginal secretions using the
SeratecH PSA semiquant assay (Seratec Diagnostica, Go ¨ttingen,
Germany). A volume of 500 ml of PSA buffer was added to the
thawed swab and was shaken for 2 hours. After centrifugation of
300 ml for 1 min at 130006g, 200 ml of supernatant was used for
testing according to the manufacturer’s instruction.
The presence of leucocytes (sensitivity, 20–25 cells/ml as trace)
and haemoglobin (sensitivity, 10 red blood cells/ml) in the
supernatant of endocervical cells samples was tested using the 5+
NL ServotestH test strips (ServopraxH GmbH, Wesel, Germany).
Cytokine and chemokine measurement
Concentrations of the inflammatory cytokines Interleukin-1a
(IL-1a), IL-1b, IL-6 and IL-12(p70); anti-inflammatory cytokine
IL-1 receptor antagonist (IL-1RA); CC chemokine macrophage
inflammatory protein 1 beta (MIP-1b); CXC chemokines IFN-c –
induced protein (IP-10) and IL-8; growth factors granulocyte-
macrophage colony-stimulating factor (GM-CSF) and granulocyte
colony-stimulating factor (G-CSF) in CVL samples were analysed
using the Bio-Plex
TM human cytokine assay kit (Bio-Rad
Laboratories NV-SA, Nazareth, Belgium) according to the
manufacturer’s instructions. Briefly, the lyophilized standard was
reconstituted for 30 minutes on ice with 500 ml PBS containing
0.5% bovine serum albumin (BSA) and then serially diluted (1 in
4). Magnetic beads coupled with unique capture antibodies were
then prepared in assay buffer and kept on ice. The assay plate was
pre-wetted with 100 ml assay buffer and drained using vacuum
filtration. The coupled beads were vortexed for 30 seconds and
50 ml added to each well in the assay plate. After two plate washes
with 100 ml wash buffer, 50 ml of standards, samples and controls
(all containing 0.5% BSA) were added to each well in the assay
plate. The plate was then sealed, covered with aluminium foil and
incubated on a shaker (500 rpm) at room temperature for 30
minutes. After this period, the plate was washed thrice with 100 ml
wash buffer using vacuum filtration and 25 ml of biotinylated
detection antibodies added to each well. The plate was sealed,
covered with aluminium foil again and incubated under the same
conditions as before for 30 minutes. After three washes, 50 mlo f
streptavidin-PE was added to the wells and incubated on a shaker
(500 rpm), at room temperature for 10 minutes. After incubation,
the plate was washed 3 times as before, 125 ml assay buffer added
to each well, covered and shaken for 4 minutes at 500 rpm.
Fluorescence data was collected using the Bio-Plex
TM array reader
and the Bio-Plex
TM Manager 5.0 software used to calculate
cytokine concentrations using a weighted five-parameter logistic
curve-fitting method on the four-fold dilution series of the standard
provided with the kit.
Elafin and b-defensin were measured by ELISA kits from R&D
Systems (Minneapolis, MN) and Phoenix Pharmaceuticals (Bur-
lingame, CA), respectively, following manufacturers’ instructions.
Optical densities were read at 450 nm with a second reference
filter of 570 nm using a Victor2 multilabel reader and WorkOut
Software (PerkinElmer, Waltham, MA). For the elafin assay, all
CVLs were tested at a 250-fold dilution in duplicates (samples
were pre-diluted in PBS with 1% BSA and then diluted 5-fold
directly on the plate using the manufacturer’s supplied reagent
diluent). For the b-defensin assay, all CVLs were tested at a 100-
fold dilution. The samples were pre-diluted 25-fold in 1% BSA/
PBS and then diluted 4-fold on the ELISA plate using the
manufacturer-supplied assay diluent. Samples with values below or
above the assay detection ranges were repeatedly tested at lower or
higher dilutions to obtain accurate protein measurements. A
quality control (QC) sample was prepared by pooling CVL
samples and running an aliquot of the QC pool on each elafin and
b-defensin plate to assess inter-assay reproducibility. The inter-
batch CV% of the QC values was 9% for the elafin ELISA kits
and 18% for the b-defensin ELISA kits. The intra-assay CV%
(mean +/2SD) assessed for duplicate samples measurements was
6.8+/2 5% for the elafin and 6.6+/2 7.8% for the b-defensin
assay. Elafin and b-defensin concentrations were normalized to
total protein determined by a BCA assay (Thermo Scientific,
Rockford, IL) using the Victor 2 counter. For total protein, all
samples were tested in duplicates at a 5-fold dilution in PBS and
retested either undiluted or 5-fold diluted if values were below or
above detection range, respectively. The total protein intra-assay
CV% was 0–10% (mean +/2 SD =2.4+/22%).
Flow cytometry
Endocervical cells were transferred into FACS tubes at 2610
5
cells per tube and spun at 5906g for 5 minutes before the
supernatant was removed. Direct staining was done by incubating
the cells with labelled antibodies for 20 to 30 minutes at 4uC. All
antibodies were from BD-biosciences, unless otherwise stated. The
following antibody-combination was used: CD14 APC (1.98 mg/
ml)/Viaprobe (PerCP)/HLA-DR FITC (0.99 mg/ml)//CD3 PE
(0.48 mg/ml). After washing in PBS, the cells were fixed with 1%
paraformaldehyde solution.
When the number of cells was sufficient, the same samples were
also used for indirect staining. Cells were first incubated with
primary antibody (anti-CCR5 [20 mg/ml]; Biolegend) for 30 min-
utes on ice before being washed in PBS and incubated for
20 minutes with secondary antibody (biotin labelled goat anti-
mouse [20 mg/ml]). After another washing step, streptavidin-PE
[20 mg/ml] was added. The samples were further washed and
mixed with diluted mouse serum. Finally, cells were directly
labelled with antibodies before FACS analysis using a BD
FACScalibur instrument. The following antibody-combinations
were used: CD3 APC (1.98 mg/ml)/Viaprobe (PerCP)/CD4
FITC (0.12 mg/ml)/CCR5 PE and CD14 APC(1.98 mg/ml)/
Viaprobe (PerCP)/CD4 FITC (0.12 mg/ml)/CCR5 PE. Isotype
controls were used to set gates. For analysis, the cells were gated on
the population that was CD3+ or CD14+. Analysis was done using
the FlowJo software (version 8.8.4 TreeStar, Inc., Ashland, OR,
USA).
Female Genital Tract Biomarkers
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Quantitative PCR for total Lactobacillus species, L. crispatus, L.
iners, L. jensenii, L. gasseri, G. vaginalis, and A. vaginae were performed
as described in Jespers et al [24]. Briefly, the primers were
synthesized by Eurogentec, Seraing, Belgium. The 25 ml PCR
mixture contained QuantiTect SYBR Green PCR (Qiagen,
Venlo, the Netherlands) with the exception of the PCR mixture
for L. vaginalis which contained Thermo Scientific Absolute SYBR
Green Mix (ABgene, Epsom, UK), 5 ml DNA extract, primers,
and Milli-Q water. The amplification reactions were performed
using the Corbett Life Science Rotor-Gene
TM 6000 (Qiagen,
Venlo, the Netherlands). For each of the organisms standard
curves were constructed. A total of 6 standards were prepared by a
tenfold dilution and within a range of 10
2 copies/5 mlt o1 0
7
copies/5 ml. The quantitative result obtained with the qPCR was
expressed in number of copies/5 ml and was back calculated
taking into account the total specimen elute volume, the volume
extracted, the DNA extract volume obtained, and volume of DNA
amplified.
Data analysis
The lower and upper limits of quantitation for each soluble
marker were defined as the lowest and highest concentration of
their standards within acceptable recovery ranges (70–130%).
CVL samples with soluble marker concentrations below the lower
detection limit in the Bio-Plex
TM assay were assigned concentra-
tions midway between the lower limit of quantitation (LLOQ) and
zero. Those above the upper detection limit were assigned values
twice the upper limit of quantitation (ULOQ). In the analyses for
associations with different factors that could influence the
expression of these soluble markers in the FGT, log10 transformed
values were used. To characterize the variation of the soluble
markers over time between and within women, we calculated the
intra-class correlation coefficient (ICC) for the analytes using the
random effects model with the equation ICC = sigmaB
2/
(sigmaB
2+sigmaW
2) where sigmaB
2 is the variance between women
and sigmaW
2 is the within woman variance in log-transformed
soluble marker concentrations. A high ICC in this context means
that there is relatively more inter-woman soluble marker
concentration variation than intra-woman variation i.e. the
analytes are more constant for each woman compared to the
total variation. ICC values were not calculated for IL-12 and GM-
CSF because of the high percentage of samples that were below
the detection limit.
We modelled analyte concentrations based on presence of
ectopy, recent sexual activity as determined by PSA detection,
menstrual cycle phase, haemoglobin presence, leucocyte presence
as well as the presence of specific bacteria in the vaginal cavity and
percentages of cervical cellular markers. All analyses were carried
out using mixed effect linear (IL-1a, IL-1b, IL-6, IL-1RA, MIP-
1b, IP-10, IL-8, G-CSF, elafin and b-defensin) or logistic
regression models (for IL-12(p70) and GM-CSF) with random
effects for women and fixed effects for assay plate to correct for
inter-assay variability. Logistic regression models were used for IL-
12(p70) and GM-CSF because 47% and 67% of the samples
respectively were below the detection limit precluding means-
based analyses. Each predictor was assessed for association with
soluble marker concentration or presence and all significant
variables were then included in a multiple predictor model. The
model was simplified using stepwise exclusion until only the
significant predictors remained in the model. All analyses were
carried out using STATA software (version 11 College Station,
Texas, USA) and graphs plotted using GraphPad Prism software
(version 5.02, GraphPad Prism Software, San Diego, California,
USA).
Results
Cohort demographics
Cohort characteristics are presented in Table 1. Four of the
women (13%) had a sexual preference for the same gender and all
of those self-reported to be sexually active during the study. Of the
remaining 26 women with a male sexual partner preference, 69%
reported sexual activity during the study. Ectopy, classified as
small, moderate or large by the study doctor following a
standardized protocol [26], was present in 20 out of the 30
women enrolled in the study. Seven of the 20 cases were classified
as small (Table 1). After screening, 84 (60%) of the total visits were
during the follicular phase (day 7) of the menstrual cycle and 57
(40%) during the luteal phase (day 21).
Clinical and laboratory diagnostic tests
Twelve samples (8.5%) were found to be PSA positive (Table 2),
an indication of recent sexual activity. All but one of the women
with positive PSA tests self-reported sexual activity during the
study period. Leucocytes were detected in the supernatant of 52%
and haemoglobin in 42% of the endocervical cells samples taken
(Table 2). All women enrolled in the study were asymptomatic for
vaginal infections with negative lab results (Trichomoniasis,
Candidiasis, CT and NG) during screening and all but one of
them did not have BV during the follow-up visits. Intermediate
Nugent scores (4 and 6) were registered at single time points (visit
4) for two different participants (participant 33 and participant 21,
respectively). Even though a Nugent score of 6 is, by definition,
intermediate, participant 21 was classified as having BV based on
her clinical presentation and the raised pH of 6.1.
Table 1. Demographic, clinical exam and behavioural data of
study population (N=30).
Demographic, clinical exam and behavioural data
N( % )
Race
Caucasian 30 (100)
Sexually active during study
Yes 22 (73)
No 8 (27)
Contraception
None 12 (40)
Intrauterine cupper device 1 (3)
Condoms 17 (57)
Cervical ectopy
Absent 10 (33)
Small 7 (23)
Moderate 12 (40)
Large 1 (4)
Partner preference
Male 26 (87)
Female 4 (13)
Age average (range) 27 (19 – 38)
doi:10.1371/journal.pone.0043951.t001
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As can be seen in figure 1, the most readily measurable
cytokines, chemokines and growth factors (Figure 1A) in CVL
showed a median concentration in the pg/ml protein range while
the anti-inflammatory IL1-RA (Figure 1A), the anti-protease elafin
as well as b-defensin (Figure 1B) were in the ng/ml range. All
analytes evaluated were detected in the majority of the CVL
samples, except for IL-12(p70) and GM-CSF that were below the
LLOQ in at least 40% of the samples. Details of the mean,
median, range and SD as well as percentages detected for each
soluble marker in the women in our cohort are given in table 3.
Longitudinal variation of soluble markers concentrations
in CVL
Inter- and intra-woman variation in soluble marker concentra-
tion differed from one analyte to another. For most of the soluble
markers the inter-woman variation was higher than the variation
between repeated samplings at different time points for the same
woman (ICC .0.50). As seen in table 4, the ICC values were
highest with IL-8, elafin and b-defensin meaning that for these
three analytes, their concentrations were relatively more constant
over time in each woman and the inter-woman variation was
higher. G-CSF had the lowest ICC value (0.41) indicating a
relatively large variation between repeated sampling for the same
woman compared to the variation in the analyte concentrations
between women. Longitudinal trends for each analyte and each
woman are shown in Figure S1.
Characterization of immune cellular markers in the
endocervical canal
A median of 3.1% of endocervical cells collected using swabs
from the study population were monocytes of which 52%
expressed both CD4 and CCR5 receptors (Figure 2). Of the total
cells, a median of 0.8% were T-cells with 60.9% combined CD4
and CCR5 expression. Even though the women in our study were
asymptomatic for FGT infections, a significant median proportion
(45.7%) of the monocytes and 15.7% of the T-cells collected from
their FGT expressed the immune activation marker HLA-DR.
Predictors of concentrations of soluble markers in CVL
Clinical predictors. Cervical ectopy was strongly and
consistently associated with higher levels of the pro-inflammatory
IL-1b, IL-8, IL-6, MIP-1b and G-CSF soluble markers in CVL
(Table 5).
The levels of IL-1a and b-defensin were elevated in the CVL of
women at day 21 of their menstrual cycle compared to day 7. In
contrast, day 21 samples had lower IL-1RA and MIP-1b
concentrations compared to day 7 samples. Lower levels of IP-
10 were also observed in day 21 samples with statistical
significance only in the univariate regression model.
In CVL samples of women with detectable white blood cells,
higher levels of IL-1a, IL-1b and G-CSF and lower levels of IP-10
were quantified.
The presence of PSA in vaginal secretions and the presence of
haemoglobin in endocervical cells’ supernatant showed single,
independent associations with higher IP-10 and IL-1RA concen-
trations in CVL, respectively.
Vaginal microbiome predictors. No significant associa-
tions were observed between any of the species over more than
one soluble marker (Table 5). Single associations were observed
between the presence of Lactobacillus iners, a non-H2O2 producer
and IL-8. GM-CSF appeared to be higher in samples from women
with Lactobacillus gasseri. Women with Lactobacillus crispatus and
Lactobacillus jensenii present showed a negative association with
cellular inflammatory markers (Table 6) but no association with
soluble inflammatory markers.
Endocervical cellular predictors. In the samples with
higher percentages of CD3 positive T-cells, concentrations of IL-
1RA, GM-CSF and elafin were also higher. Higher percentages of
CD3+ CD4+ CCR5+ cells were weakly associated with lower
levels of elafin.
Predictors of expression of cellular markers in the
endocervix
The presence of ectopy was associated with a higher percentage
of total monocytes and CD3+ CD4+ CCR5+ cells but a lower
percentage of activated monocytes (Table 6). As with soluble
markers, fluctuations with the menstrual cycle was observed with
the cellular markers. Specifically, total monocytes, CD3+ HLA-
DR+ and CD3+ CD4+ CCR5+ cells were higher on day 21
compared to day 7 of the menstrual cycle. The presence of
haemoglobin in the cells’ supernatant was associated with a higher
percentage of activated monocytes.
The impact of bacterial species on the cellular markers in the
endocervical canal in our cohort was only seen with the presence
of both L. crispatus and L. jensenii that was associated with reduced
total T-cells, CD3+ HLA-DR+ and CD3+ CD4+ CCR5+ cells in
our cohort.
Table 2. Clinical laboratory data from samples of study
population (N=141).
Clinical lab data
No. of samples (%)
Vaginal secretions pH
3.6 98 (69.5)
4.1 42 (29.8)
6.1 1 (0.7)
Nugent score
0 133 (94.3)
1 5 (3.6)
2 0 (0.0)
3 1 (0.7)
4 1 (0.7)
5 0 (0.0)
6 1 (0.7)
.6 0 (0.0)
PSA positive
Yes 12 (8.5)
No 129 (91.5)
Cells supernatant Leucocyte presence
b
Yes 70 (52)
No 65 (48)
Haemoglobin presence
b
Yes 57 (42)
No 78 (58)
b6 missing values.
PSA: prostate-specific antigen.
doi:10.1371/journal.pone.0043951.t002
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The two women with intermediate Nugent scores on their
fourth visits to the clinic (participants 21 and 33) had unique
expression profiles of specific soluble markers and bacterial species
colonization. Specifically, IL-1b, IL-8, IL-12(p70) and MIP-1b
expression in these women peaked at visit 4. Visit 4 was also the
time point at which the highest quantity of A. vaginae and L. iners
but not G. vaginalis were detected in the vaginal swab samples of
participant 21 (Figure 3). The bacterial species profile of
participant 33 was slightly different with G. vaginalis and L. iners
but not A. vaginae peaking at visit four. Interestingly, IL-6
Figure 1. Distribution of soluble marker concentrations in lavage samples. Cytokines, chemokines and growth factors were measured in
CVL samples using the Bio-Plex
TM assay while Elafin and b-defensin were quantified using ELISA. Each data point represents a single sample and the
line through data points represents the median concentration.
doi:10.1371/journal.pone.0043951.g001
Table 3. Soluble markers concentrations in CVL samples of study population.
Soluble marker Percentage detected CVL concentration (pg/ml)
Pro-inflammatory cytokines
IL-1a 99 17.51 (0.77 – 513.04)
a 35.73 (67.27)
b
IL-1b 90 6.73 (0.23 – 289.98) 23.05 (44.19)
IL-6 96 6.70 (0.15 – 624.10) 17.08 (57.33)
IL-12(p70) 53 0.50 (0.25 – 5.10) 0.61 (0.71)
Anti-inflammatory cytokines
IL-1RA 99 14,424 (3,372 – 156,688) 16,119 (14,554)
CC chemokines
MIP-1b 76 8.40 (0.65 – 140.90) 18.65 (25.48)
CXC chemokines
IP-10 100 185.55 (12.23 – 24,659) 592.47 (2,247)
IL-8 100 203.80 (7.20 – 1,128) 247.12 (204.90)
Growth factors
GM-CSF 33 0.405 (0.39 – 2.71) 0.68 (0.45)
G-CSF 100 93.36 (1.75 – 5,138) 166.74 (460.74)
Antimicrobial proteins
Elafin 100 73,465 (8,591 – 704,092) 117,706 (116,832)
b-defensin 100 5,553 (2.45 – 269,839) 16,216 (29,961)
Total protein
c 100 0.1724 (0.012 – 2.084) 0.246 (0.2312)
aMedian (minimum – maximum).
bMean (SD).
cmg/ml.
doi:10.1371/journal.pone.0043951.t003
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that time point.
Discussion
Characterization of soluble and cellular biomarkers and the
factors that influence their secretion in the FGT is undoubtedly
important for the field of anti-HIV microbicide development. Our
study describes normative expression levels of a selected panel of
soluble biomarkers in the lower FGT of a typical healthy
Caucasian population for an early phase I microbicide trial.
These biomarkers were selected based on comparison of an initial
Bio-Plex
TM run with 27 analytes with results from two different
populations in Rwanda and the United States of America as
described elsewhere [27]. In addition we characterized cervical T-
cells and monocytes, which are markers of cellular immunity,
sensitive to inflammation and potentially susceptible to HIV.
Finally, we investigated whether characteristics such as ectopy,
menstrual cycle phase, bacterial species and the presence of PSA,
leucocytes and haemoglobin in endocervical secretions were
associated with levels of soluble and cellular biomarkers in the
female genital mucosa.
Not all selected soluble biomarkers were detected in all samples.
This observation is in agreement with other studies where, for
example, GM-CSF and IL-12(p70) were also below the LLOQ for
the majority of samples regardless of sampling site (endocervix or
vagina) or specimen collection method [28]. Separately, in the
ECS samples of female adolescents in the US collected by Weck-
celH sponges, 39% of samples analysed for IL-12(p70) were below
the detection limit [29]. In a different study by Lieberman et al
[12], however, IL-12(p70) was readily detectable in all endocer-
vical secretion samples of healthy, non-pregnant women. These
discrepant results may be reflective of methodological differences
between the studies and highlight the need of developing
standardised methods that should be used for analyte detection
if results are to be favourably compared between studies for
eventual selection of biomarkers to be used in clinical trials.
Table 4. Intra-class correlation coefficients (ICC) for soluble
markers concentrations in CVL.
Soluble marker ICC
Il-1a 0.60
IL-1b 0.59
IL-6 0.51
IL-12 ND
a
IL-1ra 0.50
MIP-1b 0.61
IP-10 0.53
IL-8 0.70
GM-CSF ND
a
G-CSF 0.41
Elafin 0.72
b-defensin 0.63
aNot done due to the high percentage of samples in which the cytokine
concentrations were below the detection limits of our assay.
doi:10.1371/journal.pone.0043951.t004
Figure 2. Characterization of endocervical leucocyte markers on cells sampled using flocked swabs. Three point one percent of
endocervical cells collected using swabs were monocytes. Fifty two percent of these cells expressed both the CD4 and CCR5 receptors. Of the total
cells, 0.8% were T-cells with 60.9% combined CD4 and CCR5 expression. Even though the women in our study were asymptomatic, a significant
proportion (45.7%) of the monocytes and 15.7% of the T-cells collected from their FGT expressed the immune activation marker HLA-DR. All
percentages refer to median levels in the study population.
doi:10.1371/journal.pone.0043951.g002
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ectocervix is lined by columnar epithelium instead of the multi-
layered squamous epithelium usually found in the mature
ectocervix. A thinner mucosal barrier would imply greater
vulnerability to physical trauma during coitus leading to inflam-
mation and also exposure of sub-mucosal HIV target cells. It is not
surprising therefore that previous studies have found ectopy to be a
probable risk factor for HIV infection [30,31,32]. The strong
association of cervical ectopy with the mainly pro-inflammatory
soluble markers in our study is consistent with a recent study that
found higher levels of pro-inflammatory cytokines/chemokines in
the CVL of healthy young women with predominantly columnar
and metaplastic ectocervical epithelium compared to predominant
squamous epithelium [33] including IL-1b, IL-6 and IL-8 as
observed in our study. Previously, in vitro experiments with non-
stimulated immortalized cell lines of endocervical origin showed
higher expression of IL-6, IL-8 and M-CSF compared with cell
lines of ectocervical origin under the same conditions [34]
corroborating observations seen in women with ectopy.
Based on a general consistency between anamnestic data and
testing for PSA, this marker was found to be a reliable measure of
recent sexual activity in our study population. However, the single
Table 5. Association coefficients between soluble markers and their clinical, vaginal microbiome and endocervical cellular
predictors.
IL-1a IL-1b IL-6 IL-12
a IL-1RA MIP-1b IP-10 IL-8 GM-CSF
a G-CSF IL-1RA:IL-1(a+b) Elafin b-defensin
Cervical ectopy 0.75* 0.89* 0.56* 0.48* 0.67*
PSA presence 0.36
$ 0.30*
Menstrual cycle phase
b 0.23* 20.08* 20.14* 20.13
$ 20.24* 0.12*
Haemoglobin 0.07*
Leucocytes 0.24* 0.40* 20.13
$ 20.25* 0.31* 20.36*
L. crispatus & L. jensenii
presence
L. iners presence 0.52
$ 0.25*
L. gasseri presence 3.36*
G. vaginalis & A. vaginae
presence
20.46
$
% T-cells 0.05* 1.94* 0.04*
% Monocytes
CD3+HLADR+
CD14+HLADR+
CD3+CD4+CCR5+ 0.01
$ 20.01*
CD14+CD4+CCR5+
aAssociations between IL-12(p70), GM-CSF and their predictors were modelled using logistic regression and their association in the table described using odds ratios.
bLuteal (day 21) vs. follicular (day 7) phase.
Data on soluble marker concentrations was log-transformed before analysis. *Association coefficients representing associations that remained statistically significant in
multivariate models.
$ Coefficients representing univariate associations.
PSA: prostate-specific antigen.
doi:10.1371/journal.pone.0043951.t005
Table 6. Association coefficients between endocervical cellular markers and their clinical and vaginal microbiome predictors.
% T-cells % Monocytes CD3+ HLADR+ CD14+ HLADR+ CD3+ CD4+ CCR5+
Cervical ectopy 2.67* 216.81* 8.49*
PSA presence
Menstrual cycle phase
a 1.95* 5.27* 27.97
$ 5.02*
Haemoglobin 9.38*
Leucocytes 7.5
$
L. crispatus & L. jensenii presence 20.448* 26.94* 26.113*
L. iners presence
L. gasseri presence
G. vaginalis & A. vaginae presence
aLuteal (day 21) vs. follicular (day 7) phase.
Data on soluble marker concentrations was log-transformed before analysis. No associations were found with CD14+ CD4+ CCR5+ cells. *Association coefficients
representing associations that remained statistically significant in multivariate models.
$ Coefficients representing univariate associations.
PSA: prostate-specific antigen.
doi:10.1371/journal.pone.0043951.t006
Female Genital Tract Biomarkers
PLOS ONE | www.plosone.org 8 August 2012 | Volume 7 | Issue 8 | e43951incidence where the FGT secretions tested positive for PSA even
though the subject did not report sexual activity indicates the
importance of verification of self-reported data by laboratory
methods especially in the context of microbicide trials. Previous
reports of ectopic prostatic tissue in the upper and lower FGT
[35,36,37] that could explain exceptional detection of PSA in
semen-free vaginal samples [38] call for caution in interpretation
of results. That said, intercourse is known to disrupt the vaginal
ecosystem as constituents of seminal plasma optimize conditions to
promote conception. For example, vaginal pH is increased after
coitus due to the higher pH of semen, with semen also promoting
the influx of leucocytes and Langerhans cells into the FGT
[39,40]. Changes in vaginal bacterial species can also be expected
as during coitus, bacteria colonising the perineum could be
transferred into the vagina. The observation in our study of
increased concentrations of IP-10 (and univariately IL-6) in the
presence of PSA are in agreement with a recent study that
reported increased leukocyte recruitment and pro-inflammatory
cytokine mRNA expression in ectocervical tissue exposed to
seminal fluid during coitus [41]. This pro-inflammatory effect was
independent of the physical effects of coitus as it was not seen in
controls who used condoms. In vitro, seminal plasma induced IL-6
production in ectocervical cells but not vaginal or endocervical
cells [39]. These changes, coupled with the physical effects of
coitus, can lead to greater susceptibility to infection upon exposure
to HIV and should also be taken into account in clinical trials that
also assess the effects of microbicide compounds on the FGT.
Our study also recorded variations in concentrations of specific
soluble and cellular immune modulators with the menstrual cycle.
These variations are not surprising given the hormonal changes
occurring in the female genital tract during the course of the
menstrual cycle. Wira and Fahey even suggested a window of viral
infectivity on days 14–23 of the menstrual cycle during which FGT
immunity is suppressed by sex hormones [42]. In the CVL of
healthy pre-menopausal women, Al-Harthi and colleagues [43]
found five-fold higher expression of IL-6 and IL-1b in the follicular
compared to the luteal phase of the menstrual cycle. In contrast,
the same group found equal expression of the same cytokines in
the CVL of HIV-seropositive pre-menopausal women with
significant elevation only seen during menses [44]. Our study
group did not show differences in the expression of these two
cytokines between the follicular and luteal phases. While HIV
infection could explain differences observed in their studies and
ours, a significant difference is that our study controlled for ectopy
which was associated with both IL-1b and IL-6 expression and
could have confounded their analyses. Fleming et al [45] also
demonstrated maximal b-defensin-1 mRNA expression in the
endometrium during the mid-secretory phase and maximal b-
defensin-2 mRNA expression during menstruation. Another study
showed positive correlation of CVL levels of M-CSF with serum
levels of E2 and the E2/P ratio [46] and increased levels of IL-1b
and TGFb2 [46]. Estradiol, a hormone which is increased
together with progesterone in the luteal phase, has previously
been shown to increase mRNA expression of human b-defensin-2
by uterine epithelial cells while at the same time inhibiting the
expression of the pro-inflammatory TNF-a, IL-6 and IL-8 in vitro
[47]. This probable two-sided effect of the sex hormone is also
seen in our study where IP-10 and MIP-1b were decreased on day
21 compared to day 7 of the menstrual cycle. It remains unknown,
however, what role progesterone played in these fluctuations and
Figure 3. Case profiles of longitudinal trends of selected bacterial species counts and soluble biomarkers for women with
intermediate Nugent scores on visit 4. Two women with intermediate Nugent scores on their fourth visits to the clinic (participants 21 and 33)
had unique expression profiles of specific soluble markers and bacterial species colonization. Specifically, IL-1b, IL-8 and modestly IL-12(p70) and MIP-
1b expression in these women peaked at visit 4. Interestingly, visit 4 was also the time point at which A. vaginae and L. iners peaked for participant 21
and G. vaginalis and L. iners peaked for participant 33. Of note, IL-6 expression dipped in participant 21 but peaked in participant 33 at visit four.
doi:10.1371/journal.pone.0043951.g003
Female Genital Tract Biomarkers
PLOS ONE | www.plosone.org 9 August 2012 | Volume 7 | Issue 8 | e43951future in vitro studies would benefit from assessing the combined
effects of these sex hormones to gain a better understanding of the
in vivo situation. Of note, we demonstrated increased expression of
IL-1a and b-defensin and decreased expression of IL-1RA in the
luteal compared to the follicular phase of the menstrual cycle,
highlighting the need to take into account the menstrual cycle time
point during microbicide trials. Differential counts of L. crispatus
(0.22 log higher) and L. iners (0.83 log lower) on day 21 compared
to day 7 of the menstrual cycle were also observed in a sub-group
of our study population as described elsewhere by Jespers et al [24].
Detection of haemoglobin in cervicovaginal secretions is not
unusual even when sampling is done outside menses. Haemoglo-
bin was detected in 64% of ECS by Lieberman et al [12] although
there was no significant association with any of the analytes tested
in their study. An earlier study documented significantly higher
concentrations of IL-10 and IL-12(p70) in blood-contaminated
ECS samples compared to non-contaminated samples [29].
Haemoglobin presence in cells supernatant was positively but
weakly associated with IL-1RA and activated monocytes in our
population. These results need to be interpreted with caution as it
is possible that soluble and cellular markers of systemic origin leak
into the FGT due to trauma from sampling and are not reflective
of a local immune response at the female genital mucosa.
Leucocyte presence that is a normal marker of inflammation
was unsurprisingly positively associated with pro-inflammatory
analytes IL-1a, IL-1b and G-CSF in CVL and negatively with IL-
1RA. A recent study also found a strong correlation between the
neutrophil marker myeloperoxidase (MPO) and G-CSF that
supports neutrophil function [48].
Bacterial vaginosis, a condition in which the vagina is colonized
by anaerobic bacteria instead of the protective lactobacilli species,
has been associated with increased susceptibility to STIs and HIV
infection [49,50,51]. In our study population, the presence of both
G. vaginalis and A. vaginae was inversely correlated with IL-6. This
partial dampening of the immune response could possibly explain
the presence of these BV related organisms in healthy asymptom-
atic women. The two participants (21 and 33) with intermediate
Nugent scores had distinct vaginal microbiome and soluble marker
expression profiles. Participant 21 complained of a vaginal itch,
had a white watery discharge on examination and a vaginal pH of
6.1 during her fourth visit to the clinic. She was treated with
150mg Diflucan for clinical candidiasis and improved on the next
day. These clinical symptoms combined with a Nugent score of six
led to her classification as having BV. The Nugent scores during
her other visits were all zero. Interestingly, a longitudinal
assessment of the CVL concentrations of the soluble immune
modulators in participants 21 and 33 show similar trends (figure 3);
IL-1b, IL-8 and modestly IL-12(p70) and MIP-1b all peak during
visit 4 when these participants had intermediate Nugent scores.
These observations are partly in agreement with a different study
where both IL-1b and IL-1RA were found to be significantly
higher in women with intermediate Nugent scores compared to
women with normal Nugent scores [19]. Cauci et al [52] showed
13 fold vaginal IL-1b in women with BV in association with anti-
Gardnerella vaginalis hemolysin (Gvh) IgA response. They concluded
that the induction of the pro-inflammatory cytokine IL-1b might
be a necessary event to elicit an innate immune response to control
anaerobic genital tract infections and that high levels of vaginal IL-
1b were associated with mounting of an antigen-specific mucosal
immune response in women with bacterial vaginosis [53]. A recent
in vitro model of vaginal bacterial colonization showed that in
contrast to L. crispatus, BV-associated P. bivia and especially A.
vaginae induce increased production of pro-inflammatory chemo-
kines (e.g. IL-8) [54]. Importantly, the peaks in pro-inflammatory
cytokines observed in these two participants in our study coincide
with peaks of both A. vaginae and L. iners for participant 21 and G.
vaginalis and L. iners for participant 33 (figure 3). In participant 21,
IL-6 concentrations dipped during visit 4 when both A. vaginae and
G. vaginalis were present corroborating the inverse association seen
before. G. vaginalis was constantly present in this participant and
she only developed clinical symptoms when A. vaginae was also
present. In contrast, in participant 33 IL-6 peaked during this visit
but there was also no peak of A. vaginae, suggesting that A. vaginae
and G. vaginalis work in concert to dampen IL-6 expression and
cause BV.
The presence of both L. crispatus and L. jensenii was not related to
any of the cytokines or chemokines and had an inverse association
with the total percentage of T-cells, CD3+ HLA-DR+ and CD3+
CD4+ CCR5+ cells. This is in agreement with the knowledge that
the Lactobacillus species are the major constituents of the healthy
vaginal microbiota in women and that they have consistently been
associated with absence of vaginal symptoms, reduced risk of STIs
and a healthy pregnancy outcome [55,56]. In our healthy women
the presence of L. iners, a non-H2O2 producing bacterium, was
associated with increased IL-1b and IL-8. L. iners is present in high
numbers in women with and without BV as demonstrated by
Jespers et al [24]. In contrast to studies carried out in North
America and Europe where L. crispatus dominates, L. iners has been
shown to be the predominant species in a study in Nigeria [57].
Unpublished data from Tanzania also shows predominance in L.
iners [58] in spite of a normal flora as defined by Nugent. Assuming
that L. crispatus is the key flora of a healthy vagina, the lack of it
may be related to the high BV population prevalence in Tanzania.
In addition, Srinivasan and colleagues showed that concentrations
of L. iners increase after antibiotic treatment for BV, suggesting that
it fills in for bacteria successfully eradicated by treatment [59] and
that women who have been previously treated for BV, may be at
higher risk for recurrence. Associations between the different types
of vaginal flora in this study population are described elsewhere by
Jespers et al [24].
A potential weakness of the study is that ectopy was determined
by observation and not by photography and computer-assisted
measurement. The associations with ectopy however remained
strongly significant in the multivariate analyses ruling out the
probability that they were chance associations. Additionally,
scoring of ectopy for all participants was done by a single
physician using a documented manual, thereby excluding varia-
tion due to subjective interpretation/classification. Finally, statis-
tical significance was retained in the associations even when only
the moderate and large ectopies were considered as present and
the small ones classified as absent (data not shown). Given the
relatively large number of possible predictors and outcome
measures, only associations which were observed across several
soluble markers in CVL are expected to be reproducible. Single
associations could be due to chance and should be confirmed in
further studies.
Soluble marker concentrations described in this study can act as
reference values for further studies in women with similar or
different profiles. Comparison of concentrations across studies will
however only be feasible once sample collection, processing and
measurement methods are standardized. Most studies use tradi-
tional ELISAs or multiplex immunoassays for soluble markers
detection. The main advantage of using multiplex assays for
detection of soluble biomarkers is that very small volumes of
samples are needed to detect multiple analytes and this is
especially beneficial in the case of ECS where eluted sample
volumes are limited. Establishing the normative ranges of soluble
and cellular biomarkers in healthy populations allows for the
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conditions of immune activation and whose variations can be
universally attributed to specific predictors and hence can be
reliably used as indicators of product safety within the setting of
microbicides clinical trials. In future, clinical trials should consider
ectopy, sexual activity as determined by PSA presence, menstrual
cycle phase and presence of bacterial species in the FGT as
possible confounders when evaluating the possible inflammatory
effects of microbicide compounds in the FGT.
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